Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2015

Accounting Policies [Abstract]

Schedule Of Net Income per Ordinary Share

Basic and diluted net income per ordinary share attributable to Jazz Pharmaceuticals plc were computed as follows (in thousands, except per share amounts):

	Year Ended December 31,
	2015		2014		2013
Numerator:
Net income attributable to Jazz Pharmaceuticals plc	$	329,535	$	58,387	$	216,312
Denominator:
Weighted-average ordinary shares used in per share calculation - basic	61,232		59,746		58,298
Dilutive effect of employee equity incentive and purchase plans	1,804		2,402		1,772
Dilutive effect of warrants	—		466		1,499
Weighted-average ordinary shares used in per share calculation - diluted	63,036		62,614		61,569
Net income attributable to Jazz Pharmaceuticals plc per ordinary share :
Basic	$	5.38	$	0.98	$	3.71
Diluted	$	5.23	$	0.93	$	3.51

Schedule Of Computation Of Diluted Net Income (Loss) Per Share Having Anti-Dilutive Effect

The following table represents the weighted-average ordinary shares that were excluded from the computation of diluted net income attributable to Jazz Pharmaceuticals plc per ordinary share for the periods presented because including them would have an anti-dilutive effect (in thousands):

	Year Ended December 31,
	2015	2014	2013
Options to purchase ordinary shares and RSUs	1,609	819	1,584
1.875% exchangeable senior notes due 2021	2,878	1,112	—